TITLE

Minority government commits $20.2 billion to health

AUTHOR(S)
Kondro, Wayne
PUB. DATE
March 2005
SOURCE
CMAJ: Canadian Medical Association Journal;3/29/2005, Vol. 172 Issue 7, p863
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on the public health initiatives planned by Canadian Health Minister Ralph Goodale for fiscal year 2005 to 2006. Plan of Health Canada to improve its oversight of the drug approval process and a regulatory regime to govern the use of biological materials; Purpose of the plan of the government to buy back greenhouse gas emission reductions; Commitment of the government to cut greenhouse gas emissions by 2012.
ACCESSION #
16457536

 

Related Articles

  • Health Canada drug approval process slower than in Europe and US.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p234 

    The article deals with a report the Fraser Institute which revealed that the drug approval process by Health Canada takes nearly a year which is slower than in Europe and the U.S.

  • Clinical mistrial? (USA). Miller, Adam // CMAJ: Canadian Medical Association Journal;4/16/2013, Vol. 185 Issue 7, pE285 

    The article reports that Health Canada, the Canadian department of health, is creating awareness among consumers and health care professionals regarding the use of drug cinacalcet (sensipar) that is not approved to be prescribed to a patient under the age of 18.

  • Public health on the installment plan. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;4/27/2004, Vol. 170 Issue 9, p1378 

    Reports on the federal budget for 2004-2005 unveiled by Canadian Finance Minister Ralph Goodale that provides relatively modest new monies to improve Canada's public health system. Funding for the new Public Health Agency; Budget for the three provincial public health initiatives; Goal and...

  • "New approach" as Health Canada seeks conditional licences for drugs, new pediatric office. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/29/2005, Vol. 172 Issue 7, p864 

    Focuses on the plans of Canadian Health Minister Ujjal Dosanjh to improve drug approval system which includes conditional licensing for some drugs and the creation of a pediatric office to asses prescription drugs for children. Health budget for drug safety and speeding up drug review;...

  • Health Canada shifts focus on drug regulation.  // PharmacoEconomics & Outcomes News;8/11/2007, Issue 534, p2 

    The article deals with the Progressive Licensing Framework, a modernization project from Health Canada that will change the way drugs are assessed in Canada. The project addresses the need for increased postmarketing surveillance and takes into account the accumulation of data over a drug's...

  • Health Canada proposes new regulatory regime for drugs. Kondro, Wayne // CMAJ: Canadian Medical Association Journal Supplement;4/24/2007, Vol. 176 Issue 9, p1261 

    The article reports on the proposal of Health Canada for a new regulatory regime for drugs. Under its paper, "The Progressive Licensing Framework Concept Paper for Discussion," Health Canada proposes to lower the threshold for initial market authorization licenses in exchange for more safety and...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;12/10/2011, Issue 1381, p4 

    The article reports on the decision of Health Canada to suspend the approval of bevacizumab for patients with metastatic breast cancer.

  • Safety of drugs is threatened by looser approval process. Schafer, Arthur // CCPA Monitor;Mar2011, Vol. 17 Issue 9, p29 

    The article focuses on the looser drug approval process that threatened drugs safety in Canada. It remarks on the drug approval process and stage-managed technical consultations of Health Canada in which new drugs would be presumed to be safe unless critics can prove they will be more harmful...

  • Orexo: Abstral(R) Approved in Canada.  // Biomedical Market Newsletter;3/14/2011, p403 

    The article reports on the approval of the Abstral (R), a pain reliever drug manufactured by Orexo AB, by Health Canada, Canada's health department. It states that the product is approved for the treatment of breakthrough pain in patients receiving opioid analgesics for underlying chronic cancer...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics